Insider Buying: Aktis Oncology (NASDAQ:AKTS) Major Shareholder Purchases 835,000 Shares of Stock

Aktis Oncology (NASDAQ:AKTS) major shareholder Vida Ventures Ii, Llc purchased 835,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the purchase, the insider directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Aktis Oncology Stock Performance

Aktis Oncology stock traded down $0.65 during midday trading on Monday, hitting $21.75. The company’s stock had a trading volume of 829,486 shares, compared to its average volume of 39,873,640. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.32 and a quick ratio of 0.28. The company has a market cap of $3.36 billion, a price-to-earnings ratio of -58.78 and a beta of 1.91. Aktis Oncology has a 1-year low of $19.33 and a 1-year high of $29.16. The company has a 50-day moving average price of $0.07 and a two-hundred day moving average price of $0.09.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.